Get the Stockscreener App
4.17
2.71%
0.11
After Hours:
4.15
-0.02
-0.48%
Geron Corp stock is traded at $4.17, with a volume of 6.41M.
It is up +2.71% in the last 24 hours and up +2.71% over the past month.
Geron Corp is a clinical-stage biopharmaceutical company focused on the research and development of cancer treatments. The company's drug in development, Imelstat, is being tested for the treatment of myelodysplastic syndromes, which are disorders of the blood, and myelofibrosis, which is a rare blood cancer affecting bone marrow. The company earns revenue through collaboration agreements, milestones, royalties, and licensing arrangements. Geron possesses various rights to this drug. The company operates as a single segment being, the development of therapeutic products for oncology.
See More
Previous Close:
$4.06
Open:
$4.06
24h Volume:
6.41M
Relative Volume:
0.77
Market Cap:
$2.47B
Revenue:
$29.48M
Net Income/Loss:
$-201.19M
P/E Ratio:
-12.26
EPS:
-0.34
Net Cash Flow:
$-216.50M
1W Performance:
+4.51%
1M Performance:
+2.71%
6M Performance:
+19.83%
1Y Performance:
+118.32%
1-Day Range:
$4.00
$4.205
1-Week Range:
$3.96
$4.205
52-Week Range:
$1.64
$5.34
Geron Corp Stock (GERN) Company Profile
Name
Geron Corp
Sector
Industry
Phone
(650) 473-7700
Address
919 EAST HILLSDALE BOULEVARD, FOSTER CITY, CA
Compare GERN with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
GERN
Geron Corp
|
4.17 | 2.47B | 29.48M | -201.19M | -216.50M | -0.34 |
|
VRTX
Vertex Pharmaceuticals Inc
|
464.56 | 119.70B | 10.63B | -479.80M | -1.35B | 13.33 |
|
REGN
Regeneron Pharmaceuticals Inc
|
754.87 | 82.75B | 13.85B | 4.65B | 3.32B | 35.06 |
|
ARGX
Argen X Se Adr
|
614.59 | 36.73B | 1.86B | -40.29M | -1.28B | -4.16 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
253.74 | 32.53B | 2.09B | -332.26M | 16.06M | -4.14 |
|
BNTX
Biontech Se Adr
|
120.72 | 28.50B | 3.30B | -501.07M | 1.03B | 11.54 |
Geron Corp Stock (GERN) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Nov-05-24 | Initiated | H.C. Wainwright | Buy |
| Oct-16-24 | Initiated | Scotiabank | Sector Outperform |
| Sep-09-24 | Initiated | Leerink Partners | Outperform |
| Apr-30-24 | Downgrade | Robert W. Baird | Outperform → Neutral |
| Apr-29-24 | Initiated | TD Cowen | Buy |
| Mar-15-24 | Reiterated | Needham | Buy |
| Sep-12-23 | Upgrade | Goldman | Neutral → Buy |
| Mar-28-23 | Initiated | Goldman | Neutral |
| Oct-28-22 | Initiated | Wedbush | Outperform |
| Jul-28-22 | Resumed | B. Riley Securities | Buy |
| Nov-02-21 | Initiated | Robert W. Baird | Outperform |
| Feb-18-21 | Resumed | B. Riley Securities | Buy |
| Aug-03-20 | Initiated | Stifel | Buy |
| Nov-19-19 | Resumed | B. Riley FBR | Buy |
| Sep-03-19 | Initiated | H.C. Wainwright | Buy |
| Aug-15-19 | Initiated | Cantor Fitzgerald | Overweight |
| Apr-09-19 | Upgrade | Needham | Hold → Buy |
| Jan-31-19 | Upgrade | B. Riley FBR | Neutral → Buy |
| Oct-02-18 | Downgrade | B. Riley FBR | Buy → Neutral |
| Jul-05-18 | Initiated | B. Riley FBR, Inc. | Buy |
| Sep-13-16 | Reiterated | FBR & Co. | Outperform |
| Sep-13-16 | Reiterated | FBR Capital | Outperform |
| Dec-07-15 | Reiterated | Piper Jaffray | Overweight |
| Apr-21-15 | Initiated | Oppenheimer | Outperform |
| Jun-12-14 | Upgrade | MLV & Co | Hold → Buy |
| Mar-12-14 | Downgrade | MLV & Co | Buy → Hold |
| Dec-10-13 | Reiterated | MLV & Co | Buy |
| Dec-10-13 | Upgrade | Needham | Hold → Buy |
| Nov-08-13 | Reiterated | MLV & Co | Buy |
| Oct-16-13 | Initiated | MLV & Co | Buy |
| Aug-30-12 | Initiated | Stifel Nicolaus | Buy |
| Jun-28-12 | Initiated | Needham | Hold |
View All
Geron Corp Stock (GERN) Latest News
Geron to Present at Evercore ISI HealthCONx Conference This December | GERN Stock News - StockTitan
Geron Corp. (GERN): Among the NASDAQ Stocks with Biggest Upside Potential According to Analysts - Insider Monkey
12 NASDAQ Stocks with Biggest Upside Potential According to Analysts - Insider Monkey
Geron Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - Yahoo Finance
Geron: A Strong Launch And Financial Deals Make It Attractive (NASDAQ:GERN) - Seeking Alpha
Akin Advises Pharmakon Advisors in its $250 Million Debt Financing for Geron Corporation - Akin Gump Strauss Hauer & Feld LLP
First Turn Management LLC Takes $14.19 Million Position in Geron Co. (NASDAQ:GERN) - MarketBeat
RA Capital Management's Strategic Acquisition of Geron Corp Shar - GuruFocus.com
Deep Track Capital's Strategic Reduction in Geron Corp Holdings - GuruFocus.com
RTW INVESTMENTS, LP Acquires New Stake in Geron Corp - GuruFocus.com
GERNGeron Corp Latest Stock News & Market Updates - StockTitan
Geron's SWOT analysis: oncology biotech stock poised for growth By Investing.com - Investing.com UK
Geron Strengthens Leadership: Top Oncology Expert Dr. Eid Joins as EVP of R&D | GERN Stock News - StockTitan
Geron to Present at Stifel 2024 Healthcare ConferenceKey Management Insights Coming | GERN Stock News - StockTitan
B. Riley Predicts Geron's FY2026 Earnings (NASDAQ:GERN) - MarketBeat
Equities Analysts Offer Predictions for Geron Q2 Earnings - MarketBeat
HC Wainwright Weighs in on Geron's Q1 Earnings (NASDAQ:GERN) - MarketBeat
Analysts Are Upgrading Geron Corporation (NASDAQ:GERN) After Its Latest Results - Yahoo Finance
Geron Corporation (NASDAQ:GERN) Q3 2024 Earnings Call Transcript - Insider Monkey
Geron Third Quarter 2024 Earnings: Beats Expectations - Yahoo Finance
Geron Corp (GERN) Q3 2024 Earnings Call Highlights: Strong Rytelo Launch and Strategic ... By GuruFocus - Investing.com Canada
Geron Corp (GERN) Q3 2024 Earnings Call Highlights: Strong Rytel - GuruFocus.com
Geron Secures $250M Funding and Strong Q3 Sales - Yahoo Finance
Geron Corporation’s Q3 2024: Strong RYTELO Launch and Financial Growth - TipRanks
Geron started at buy by H.C. Wainwright ahead of Q3 earnings - MSN
Geron: Q3 Earnings Snapshot - Houston Chronicle
Geron (GERN) Q3 2024 Earnings Call Transcript - Barchart
Geron (NASDAQ:GERN) Sees Strong Trading VolumeTime to Buy? - MarketBeat
Geron: A Post Earnings And Funding Announcement Assessment (NASDAQ:GERN) - Seeking Alpha
Geron earnings beat by $0.04, revenue topped estimates - Investing.com
Royalty Pharma to acquire royalty interest in Geron’s RYTELO for $125M - TipRanks
Geron price target raised to $9 from $8 at H.C. Wainwright - TipRanks
Geron (GERN) Reports Q3 Loss, Tops Revenue Estimates - Yahoo Finance
Geron spikes after Q3 beat and $375M funding deal - MSN
Geron sees FY24 operating expenses $260M-$270M - TipRanks
What is HC Wainwright's Estimate for Geron Q4 Earnings? - MarketBeat
Geron secures up to $375 million in financing - Investing.com
Geron stock spikes on Q3 beat and funding deal (GERN:NASDAQ) - Seeking Alpha
Royalty Pharma plc (RPRX) to Acquire Royalty Interest in Geron’s (GERN) RYTELO for $125M - StreetInsider.com
Royalty Pharma to Acquire Royalty Interest in Geron’s RYTELO for $125 Million - StockTitan
Geron Corporation Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2024 - Marketscreener.com
Geron Corporation Reports Third Quarter 2024 Financial Results and Recent Business Highlights - The Bakersfield Californian
Geron Secures Massive $375M Financing Deal for RYTELO Launch, Backed by Royalty Pharma | GERN Stock News - StockTitan
Brokerages Set Geron Co. (NASDAQ:GERN) Price Target at $7.05 - MarketBeat
HC Wainwright Estimates Geron's Q3 Earnings (NASDAQ:GERN) - MarketBeat
H.C. Wainwright: 'Rytelo off to a strong launch,' assigns Buy to Geron shares - Investing.com
Analyst Ratings For Geron - Benzinga
Geron's RYTELO Shows Strong Clinical Results in MDS Patients Ahead of ASH Meeting | GERN Stock News - StockTitan
HC Wainwright Begins Coverage on Geron (NASDAQ:GERN) - MarketBeat
Geron initiated with a Buy at H.C. Wainwright - TipRanks
Geron Announces New Data to be Presented at Upcoming ASH Annual Meeting Highlighting the Potential of RYTELO™ (imetelstat) in Myeloid Hematologic Malignancies - Yahoo Finance
Geron Corp Stock (GERN) Financials Data
Revenue
Net Income
Cash Flow
EPS
1.35%
0.87%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):